Anúncio
Anúncio

PMCB

PMCB logo

PharmaCyte Biotech, Inc. Common Stock

0.84
USD
Patrocinado
+0.06
+8.29%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

0.90

+0.07
+8.01%

Relatórios de Lucros PMCB

Rácio de surpresa positiva

PMCB separação 2 de 4 últimas estimativas.

50%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/
--
Mudanças implicadas de Q2 26 (Revenue/ EPS)
--
/
--
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
--

PharmaCyte Biotech, Inc. Common Stock earnings per share and revenue

On 12 de dez. de 2025, PMCB reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q3 26, -- analistas forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q2 2026, PharmaCyte Biotech, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on -- analistas, PharmaCyte Biotech, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q3 2026.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio